Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Catalent News
  4.  » Biohaven announces FDA acceptance of 505(b)(2) NDA filing for BHV-0223
RSS feed icon

Biohaven announces FDA acceptance of 505(b)(2) NDA filing for BHV-0223

Catalent welcomes the announcement by its partner, Biohaven, of the FDA’s Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Learn More